Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis

Inclusion Criteria: * Male or female subjects, aged between 18 and 75 years old (inclusive). * Subjects who are capable of understanding the nature of the study and voluntarily signing the Informed consent form (ICF). * Prior treatment with systemic corticosteroids (SCS) within two years before screening, and/or contraindicate to or intolerance to systemic corticosteroids, and/or with prior surgery to nasal polyps 6 months before the screening. Exclusion Criteria: * Allergic or intolerant to mometasone furoate spray or CM326. * Have received allergen-specific immunotherapy that initiated within 3 months prior to randomization or planned to be initiated during the study period. * Participated study of CM326. * Systemic immunosuppressive therapy for inflammatory or autoimmune diseases within 8 weeks or 5 half-lives prior to baseline (whichever is longer). * Starting leukotriene receptor antagonist therapy within 4 weeks prior to baseline. * With antrochoanal polyps. * With severe deviation of the nasal septum occludes at least one nostril. * With persistent rhinitis medicamentosas. * With acute sinusitis, nasal infection, or upper respiratory tract infection at screening. * Have symptoms or whose CT scan suggests allergic fungal sinusitis. * With malignant or benign neoplasm of nasal cavities. * With other uncontrolled serious diseases or recurrent chronic diseases. * Have severe hepatic and renal impairment.